Orchard Therapeutics Plc (ORTX) Misses Q4 EPS by 2c

Orchard Therapeutics Plc (NASDAQ: ORTX) reported Q4 EPS of ($0.46), $0.02 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $595 thousand versus the consensus estimate of $1 million.

“We are inspired by the possibilities ahead for Orchard in 2020 and beyond to bring the benefits of our gene therapy approach to patients worldwide,” said Mark Rothera, president and chief executive officer of Orchard. “As we prepare for the anticipated EU approval of OTL-200 for MLD, we are strengthening the foundation of our global commercial infrastructure that could one day support multiple potentially transformative products. We are also continuing to propel the business forward by advancing our next wave of proof-of-concept trials evaluating the potential for gene-corrected stem cells in a broader range of neurometabolic disorders. With strong execution in 2019 and a solid balance sheet heading into 2020, we are well-positioned to deliver value to our shareholders.”

For earnings history and earnings-related data on Orchard Therapeutics Plc (ORTX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Z Squared outlines AI power strategy and Paradox Data acquisition
• Reading (RDI) Tops Q2 EPS by 4c